Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2025; 15(4): 100041
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.100041
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.100041
Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature
Alissar El Chediak, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States
Dhruv Ahuja, Department of Medicine, Indira Gandhi Hospital, New Delhi 110077, India
Cassandra Bruns, Rachael Simard, Kellie Spence, Kidney and Pancreas Transplant Program, Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States
Amna Gul, Department of Medicine, Aga Khan University, Karachi 74800, Pakistan
Rachel C Forbes, Division of Kidney and Pancreas Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States
Beatrice P Concepcion, Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637, United States
Co-first authors: Alissar El Chediak and Dhruv Ahuja.
Author contributions: El Chediak A, Ahuja D and Concepcion BP were responsible for conception or design of the work, acquisition, analysis, and interpretation of data for the work, drafting the work, final approval of the version to be published; Bruns C, Simard R, Spence K, Gul A, Forbes RC were responsible for acquisition of data for the work, revising it critically for important intellectual content, final approval of the version to be published.
Institutional review board statement: The Vanderbilt University Institutional Review Board (IRB No. 210132) approved the study.
Informed consent statement: Requirement for informed consent was waived by the Institutional Review Board due to minimal risk to participants.
Conflict-of-interest statement: The authors declare no conflict-of-interest.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Beatrice P Concepcion, MD, Associate Professor, Department of Medicine, Section of Nephrology, University of Chicago, 5841 S. Maryland Ave MC 5100, Chicago, IL 60637, United States. beatrice.concepcion@bsd.uchicago.edu
Received: August 5, 2024
Revised: February 23, 2025
Accepted: April 16, 2025
Published online: December 18, 2025
Processing time: 470 Days and 12.1 Hours
Revised: February 23, 2025
Accepted: April 16, 2025
Published online: December 18, 2025
Processing time: 470 Days and 12.1 Hours
Core Tip
Core Tip: This study reports on the use of tixagevimab/cilgavimab in newly transplanted kidney recipients. There were no adverse events related to the drug, and a 12.5% breakthrough infection rate, 4.5% hospitalization rate, and no deaths. The results suggest reassuring outcomes in newly transplanted kidney recipients who received tixagevimab/cilgavimab 300 mg/300 mg as prevention for coronavirus disease 2019 during the omicron wave. A systematic literature review of studies reporting outcomes of solid organ transplant recipients who received tixagevimab/cilgavimab found that the drug was well tolerated and a higher dose (300 mg/300 mg) was more protective against breakthrough infections and hospitalization than the lower dose (150 mg/150 mg).